NEWS HIGHLIGHTSMedia Articles Related to Hydralazine and Hydrochlorothiazide (Hydralazine / Hydrochlorothiazide)
Seasoning May Cut Salt Needs in Hypertension (CME/CE)
Source: MedPage Today Primary Care [2013.05.18]
SAN FRANCISCO (MedPage Today) -- A greater taste for salt among older hypertensive adults might be sated by seasoning instead, a small experimental study showed.
Surprising Findings On Hypertension In Adolescents
Source: Hypertension News From Medical News Today [2013.05.07]
Teenagers with high blood pressure appear to have better psychological adjustment and enjoy higher quality of life than those with normal blood pressure, suggests a study in the May issue of Psychosomatic Medicine: Journal of Biobehavioral Medicine, the official journal of the American Psychosomatic Society...
Safety-Net Clinics Face Challenges Controlling Hypertension In Their Patients
Source: Hypertension News From Medical News Today [2013.04.19]
Federally funded safety-net clinics for the uninsured lag behind other health care providers in controlling blood pressure among the low-income patients who rely on them for care, a new Michigan State University analysis suggests...
Relationship Between Obesity, Heart Disease And Hypertension
Source: Hypertension News From Medical News Today [2013.04.13]
Obesity, heart disease, and high blood pressure (hypertension) are all related, but understanding the molecular pathways that underlie cause and effect is complicated...
Preeclampsia (Pregnancy Induced Hypertension)
Source: MedicineNet Hydronephrosis Specialty [2012.05.21]
Title: Preeclampsia (Pregnancy Induced Hypertension)
Category: Diseases and Conditions
Created: 11/14/1998 4:06:00 PM
Last Editorial Review: 5/21/2012 12:00:00 AM
Published Studies Related to Hydralazine and Hydrochlorothiazide (Hydralazine / Hydrochlorothiazide)
Hydralazine, hydrochlorothiazide and ampicillin associated with retroperitoneal fibrosis: case report. [1989.04]
A case of retroperitoneal fibrosis possibly associated with hydralazine, hydrochlorothiazide and ampicillin therapy is reported..
Plasma lipid profiles and antihypertensive agents: effects of lisinopril, enalapril, nitrendipine, hydralazine, and hydrochlorothiazide. [1988.07]
Previous studies have documented potentially adverse effects of diuretics and beta-blocking agents on plasma lipid profiles. This study was designed to establish the effects on lipid profiles of the angiotensin-converting enzyme inhibitors lisinopril and enalapril, alone and in combination with hydrochlorothiazide (HCTZ), the calcium-channel blocker nitrendipine, HCTZ, and hydralazine...
Clinical Trials Related to Hydralazine and Hydrochlorothiazide (Hydralazine / Hydrochlorothiazide)
Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer [Completed]
The current standard for locally advanced cervical cancer is concurrent cisplatin-based
chemotherapy, however, the treatment results need to be improved. Epigenetic aberrations play
an important role in cancer progression by silencing growth regulatory genes and there is now
evidence that inhibitors of DNA methylation and HDAC inhibition synergize the radiation and
chemotherapy effects.
Objective. To determine response rate, safety and biological effects of hydralazine and
magnesium valproate when added to cisplatin chemoradiation.
Hypothesis. Hydralazine and magnesium valproate associated to chemoradiation will increase
the clinical complete response rate to 95% as compared to 75% as seen in historical controls
treated with cisplatin chemoradiation in FIGO stage IIIB patients.
Metodology. A total of 17 FIGO stage IIIB patients with histologically confirmed cervical
carcinoma with no previous treatment will be included. Patients will be typed for acetylator
status and and then receive either 182 or 83 mg of hydralazine, and magnesium valproate at
40mg/Kg from day - 7 to the end of chemoradiation (external and brachytherapy). Clinical
response rate, safety and transcriptome changes will be analyzed.
Hydralazine and Valproate Added to Chemotherapy for Breast Cancer [Terminated]
Aberrant DNA methylation and histone deacetylation participate in cancer development and
progression, as epigenetic alterations are common to breast cancer, in this phase II study,
the demethylating hydralazine plus the HDAC inhibitor magnesium valproate will be added to
neoadjuvant doxorubicin and cyclophosphamide in locally advanced breast cancer to assess
their safety and biological efficacy.
Hydralazine Valproate for Ovarian Cancer [Recruiting]
The current standard for recurrent, persistent or metastatic cisplatin-resistant ovarian
cancer is palliative chemotherapy with either topotecan, liposomal doxorubicin or
gemcitabine, however, the results need to be improved. Epigenetic aberrations play an
important role in cancer progression by silencing growth regulatory genes and there is now
evidence that inhibitors of DNA methylation and HDAC inhibition synergize the cytotoxicity
of chemotherapy.
Objective. To determine the superiority of epigenetic therapy with hydralazine and valproate
plus topotecan over placebo plus topotecan upon progression-free survival.
Hypothesis. Hydralazine and magnesium valproate associated to topotecan will increase
progression-free survival from 6 to 9 months as compared with the same regimen of
chemotherapy plus placebo.
Hydralazine Valproate for Cervical Cancer [Recruiting]
The current standard for recurrent, persistent or metastatic cervical cancer is palliative
chemotherapy with cisplatin topotecan, however, the results need to be improved. Epigenetic
aberrations play an important role in cancer progression by silencing growth regulatory
genes and there is now evidence that inhibitors of DNA methylation and HDAC inhibition
synergize the cytotoxicity of chemotherapy.
Objective. To determine the superiority of epigenetic therapy with hydralazine and valproate
plus standard cisplatin topotecan against placebo plus cisplatin topotecan upon
progression-free survival.
Hypothesis. Hydralazine and magnesium valproate associated to cisplatin topotecan will
increase progression-free survival from 4. 6 to 7. 6 months as compared with the same regimen
of chemotherapy plus placebo.
Hydralazine Versus Labetalol for the Management of Hypertensive Disorders of Pregnancy [Recruiting]
Hypertensive crisis (defined as a systolic pressure > 160mmHg or a diastolic pressure >
110mmHg) in patients with a hypertensive disorder of pregnancy is a serious complication
with severe and even deadly consequences. The management in this population had been
studied, but no consensus has been reached with regards to which treatment is better. Our
study will compare two drugs: Hydralazine and Labetalol for the management of hypertensive
crisis.
|
